About Actin-binding protein WASF3
Actin-binding protein WASF3 (WASF3) is a protein
from Homo sapiens identified by UniProt accession
Q9UPY6, 502 residues long.
MolForge cross-references it against 0 known binders and
94 disease associations.
Target properties
| Protein name | Actin-binding protein WASF3 |
| UniProt accession | Q9UPY6 |
| Gene | WASF3 |
| Organism | Homo sapiens |
| Length | 502 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (94)
Diseases linked to this target (Open Targets).
- systolic blood pressure · score 0.37
- alcohol consumption measurement · score 0.37
- neurodegenerative disease · score 0.36
- lean body mass · score 0.34
- PHF-tau measurement · score 0.33
- platelet component distribution width · score 0.33
- appendicular lean mass · score 0.33
- breast adenocarcinoma · score 0.25
- fat body mass · score 0.23
- base metabolic rate measurement · score 0.23
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q9UPY6-F1 | alphafold | PREDICTED | 65.54 | — |
Amino-acid sequence (502 residues)
MPLVKRNIEP RHLCRGALPE GITSELECVT NSTLAAIIRQ LSSLSKHAED IFGELFNEAN NFYIRANSLQ DRIDRLAVKV TQLDSTVEEV SLQDINMKKA FKSSTVQDQQ VVSKNSIPNP VADIYNQSDK PPPLNILTPY RDDKKDGLKF YTDPSYFFDL WKEKMLQDTE DKRKEKRRQK EQKRIDGTTR EVKKVRKARN RRQEWNMMAY DKELRPDNRL SQSVYHGASS EGSLSPDTRS HASDVTDYSY PATPNHSLHP QPVTPSYAAG DVPPHGPASQ AAEHEYRPPS ASARHMALNR PQQPPPPPPP QAPEGSQASA PMAPADYGML PAQIIEYYNP SGPPPPPPPP VIPSAQTAFV SPLQMPMQPP FPASASSTHA APPHPPSTGL LVTAPPPPGP PPPPPGPPGP GSSLSSSPMH GPPVAEAKRQ EPAQPPISDA RSDLLAAIRM GIQLKKVQEQ REQEAKREPV GNDVATILSR RIAVEYSDSD DDSEFDENDW SD
Explore Actin-binding protein WASF3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets